Zoryve Psoriasis Cream Now Approved for Kids as Young as 2
Plaque psoriasis in young children presents a particular treatment challenge for dermatologists and parents alike. Topical steroids remain a mainstay treatment for psoriasis at any age, but long-term or frequent steroid use on a young child's skin carries real risks, including thinning skin and other side effects that make doctors and parents understandably cautious about relying on them as an everyday, ongoing treatment. Non-steroidal alternatives specifically studied and approved for very young children have simply been in short supply.
On June 29, 2026, Arcutis Biotherapeutics announced the FDA had expanded approval of Zoryve (roflumilast) cream 0.3% to include children with plaque psoriasis as young as age 2. Zoryve works as a topical PDE4 inhibitor, a mechanism that calms inflammatory signaling in the skin without the side effect profile associated with steroids, and this expanded approval makes it the first once-daily, steroid-free topical treatment cleared for plaque psoriasis in this young age group.
The expanded approval was supported by clinical studies showing that Zoryve cream 0.3% performed consistently across age groups, with safety and efficacy in the youngest patients tracking closely with what's already been established in older children and adults. That consistency matters clinically, since it means doctors aren't extrapolating from adult data alone when treating very young patients, they now have direct evidence in this specific age group.
Zoryve was originally approved for older children and adults, and this pediatric expansion builds on several years of real-world use in those groups, plus a separate lower-strength formulation already approved for atopic dermatitis in similarly young children, giving doctors a reasonably established safety track record to draw on even as the approved age range extends downward.
Beyond the age expansion, the approval reinforces something that's been true of Zoryve cream 0.3% more broadly: it's approved for use anywhere on the body with no restrictions on how long it can be used, unlike topical steroids, which are typically limited to specific body areas and shorter treatment durations because of their side effect profile. For families managing a young child's psoriasis, that combination, once-daily dosing, no steroid-related restrictions, and now formal approval down to age 2, meaningfully simplifies what has often been a frustrating, trial-and-error treatment process.
If your young child has been diagnosed with plaque psoriasis, this expanded approval is worth raising with your pediatric dermatologist, particularly if steroid side effects or usage restrictions have been a source of frustration in managing their skin day to day.